MA46228A - Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll - Google Patents

Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll

Info

Publication number
MA46228A
MA46228A MA046228A MA46228A MA46228A MA 46228 A MA46228 A MA 46228A MA 046228 A MA046228 A MA 046228A MA 46228 A MA46228 A MA 46228A MA 46228 A MA46228 A MA 46228A
Authority
MA
Morocco
Prior art keywords
menin
mll interaction
bicyclic inhibitors
fusion
fusion bicyclic
Prior art date
Application number
MA046228A
Other languages
English (en)
Inventor
Patrick René Angibaud
Barbara Herkert
Daniel Jason Krosky
Vineet Pande
Aaron Nathaniel Patrick
Olivier Alexis Georges Querolle
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46228A publication Critical patent/MA46228A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA046228A 2016-09-14 2017-09-13 Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll MA46228A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394291P 2016-09-14 2016-09-14
EP16192424 2016-10-05
EP17180228 2017-07-07

Publications (1)

Publication Number Publication Date
MA46228A true MA46228A (fr) 2019-07-24

Family

ID=59901513

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046228A MA46228A (fr) 2016-09-14 2017-09-13 Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll

Country Status (13)

Country Link
US (2) US10611778B2 (fr)
EP (1) EP3512858B1 (fr)
JP (1) JP7033141B2 (fr)
KR (1) KR102493364B1 (fr)
CN (1) CN109715634B (fr)
AU (1) AU2017326485B2 (fr)
CA (1) CA3033020A1 (fr)
ES (1) ES2966316T3 (fr)
IL (1) IL265231B (fr)
MA (1) MA46228A (fr)
MX (1) MX389598B (fr)
TW (1) TWI753016B (fr)
WO (1) WO2018050684A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (fr) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
ES2966316T3 (es) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
WO2019060365A1 (fr) 2017-09-20 2019-03-28 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
WO2019120209A1 (fr) 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Inhibiteurs spiro exo-aza de l'interaction ménine-mll
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
US20210198283A1 (en) * 2018-08-08 2021-07-01 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
EA202190623A1 (ru) 2018-08-27 2021-05-21 Сумитомо Дайниппон Фарма Ко., Лтд. Оптически активное азабициклическое производное
BR112021007421A2 (pt) 2018-12-06 2021-08-03 Daiichi Sankyo Company, Limited derivado de cicloalcano-1,3-diamina
CN118255773A (zh) 2019-12-19 2024-06-28 詹森药业有限公司 取代的直链螺环衍生物
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
GEAP202316332A (en) 2021-01-29 2023-12-11 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
CA3215379A1 (fr) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Derives spiro substitues
JP2024521879A (ja) 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
JP2024525145A (ja) 2021-06-17 2024-07-10 ヤンセン ファーマシューティカ エヌ．ベー． がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
EP4358954A4 (fr) * 2021-06-26 2025-09-03 Cedilla Therapeutics Inc Inhibiteurs de cdk2 et leurs procédés d'utilisation
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
ES2282731T3 (es) * 2002-12-23 2007-10-16 Janssen Pharmaceutica N.V. Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005110410A2 (fr) 2004-05-14 2005-11-24 Abbott Laboratories Inhibiteurs de kinases en tant qu'agents therapeutiques
US20080102068A1 (en) * 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
WO2012082436A2 (fr) 2010-12-03 2012-06-21 Epizyme, Inc. Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
EP2646454B1 (fr) 2010-12-03 2015-07-08 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
CN103664991B (zh) * 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100695A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
PL2935222T3 (pl) 2012-12-21 2019-02-28 Epizyme Inc Inhibitory PRMT5 i ich zastosowania
WO2014164543A1 (fr) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprenant des composés thiénopyrimidine et thiénopyridine et procédés d'utilisation associés
WO2015191701A1 (fr) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Échafaudages pour inhibiteurs d'interactions ménine-mll
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2016040330A1 (fr) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation
WO2016081732A1 (fr) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thiénopyrimidines et utilisations de celles-ci
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
KR20180103053A (ko) 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
WO2017192543A1 (fr) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Pipéridines en tant qu'inhibiteurs de ménine
WO2017207387A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
CA3024180A1 (fr) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibiteurs de l'interaction menine-mll
WO2018024602A1 (fr) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro [4,4] nonanes
WO2018050686A1 (fr) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Inhibiteurs spiro bicycliques de l'interaction ménine-mll
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
ES2966316T3 (es) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma

Also Published As

Publication number Publication date
CA3033020A1 (fr) 2018-03-22
TW201823249A (zh) 2018-07-01
AU2017326485B2 (en) 2021-04-22
EP3512858A1 (fr) 2019-07-24
US20190218230A1 (en) 2019-07-18
CN109715634B (zh) 2022-09-27
US10611778B2 (en) 2020-04-07
JP7033141B2 (ja) 2022-03-09
JP2019530745A (ja) 2019-10-24
AU2017326485A1 (en) 2019-02-21
EP3512858B1 (fr) 2023-11-08
KR20190046888A (ko) 2019-05-07
BR112019004764A2 (pt) 2019-05-28
IL265231B (en) 2021-06-30
MX389598B (es) 2025-03-11
MX2019002959A (es) 2019-07-04
WO2018050684A1 (fr) 2018-03-22
TWI753016B (zh) 2022-01-21
EP3512858C0 (fr) 2023-11-08
KR102493364B1 (ko) 2023-01-27
ES2966316T3 (es) 2024-04-19
IL265231A (en) 2019-05-30
CN109715634A (zh) 2019-05-03
US20200172556A1 (en) 2020-06-04
US10975100B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
IL321844A (en) Menin–MLL interaction inhibitors
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3518934A4 (fr) Inhibiteurs de l'adénosine 5'-nucléotidase
DK3507291T3 (da) Kondenserede bicykliske sgc-stimulatorer
MA46180A (fr) Analogues de l'amyline
EP3430731A4 (fr) Architecture d'iugw
FI20165061L (fi) Aluksen itsenäinen käyttö
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
EP3514431A4 (fr) Joint fileté
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
DK3432872T3 (da) Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom
EP3484854A4 (fr) Inhibiteurs de l'apoptose
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE
ITUA20161599A1 (it) Contenitore e procedimento per la realizzazione dello stesso
EP3446828A4 (fr) Centre d'usinage
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3534888A4 (fr) Modulateurs allostériques hétéroaryle bicycliques substitués de récepteurs nicotiniques de l'acétylcholine
EP3443104A4 (fr) Jeu d'outils de la voie des substances florigènes
EP3331887A4 (fr) Benzodiazépines en tant qu'inhibiteurs de bromodomaines
IL259561B (en) Methods of predicting progression of barrett's esophagus